LIfT BioSciences Unveils Promising Preclinical Data for First-in-Class Neutrophil Cell Therapy at SITC 2025
Key Insights
LIfT BioSciences (search) presented preclinical data on its first-in-class Immunomodulatory Alpha Neutrophils (search) (IMANs (search)) at the 40th Society for Immunotherapy of Cancer (search), demonstrating potential to restore innate immune competence and remodel tumor microenvironments.
IMANs (search) exhibited physiological biodistribution, safety, and consistent tumor infiltration in vivo, resulting in recruitment of T and NK cells with enhanced effector cell recruitment and increased tumor cell death.
The therapy synergized with CAR-T cells (search) to enhance tumor clearance in treatment-resistant cervical and pancreatic cancer (search) models, showing robust antigen-independent cytotoxicity across multiple tumor types.
LIfT BioSciences (search), a rapidly emerging biotech company and global leader in neutrophil immunotherapies, presented compelling preclinical data on its first-in-class Immunomodulatory Alpha Neutrophils (search) (IMANs (search)) at the 40th Society for Immunotherapy of Cancer (search) conference in National Harbor, Maryland. The data demonstrates the potential of IMANs to restore innate immune competence and remodel the tumor microenvironment in support of anti-tumor immunity.
Robust Safety Profile and Tumor Infiltration
The preclinical studies revealed that IMANs (search) exhibited physiological biodistribution, safety, and consistent tumor infiltration in vivo. This tumor infiltration resulted in the recruitment of T and NK cells, suggesting the therapy's ability to mobilize the body's natural immune defenses against cancer (search).
Enhanced Anti-Tumor Activity and Synergistic Effects
In preclinical tumor models, IMANs (search) demonstrated enhanced effector cell recruitment, which resulted in increased tumor cell death. Notably, the therapy showed synergistic effects when combined with CAR-T cells (search), enhancing tumor clearance in models of treatment-resistant cervical and pancreatic cancers. This combination approach addresses a critical challenge in oncology, where treatment resistance often limits therapeutic options.
Broad-Spectrum Cytotoxicity
The research revealed that IMANs (search) exhibited robust, antigen-independent cytotoxicity across multiple tumor types. This characteristic demonstrates the therapy's potential to target antigen escape variants that drive metastatic progression in cancer (search), addressing a key mechanism by which tumors evade immune surveillance.
Clinical and Commercial Advantages
According to Alex Blyth, Chief Executive Officer of LIfT BioSciences (search), the IMAN platform offers significant advantages over existing cell therapies. "With scalable, off-the-shelf manufacturing and a lower cost profile than many current cell therapies, IMANs (search) have the potential to deliver broad clinical impact across oncology and immune-mediated diseases," Blyth commented.
The CEO emphasized the growing recognition of the platform's transformative potential in immuno-oncology, noting that "our findings highlight how our first-in-class IMANs (search) can restore innate immune competence and drive adaptive immune activation in solid tumors."
Conference Presentation Details
The data was presented in a poster titled "IMANs (search): A transformative allogeneic neutrophil cell therapy for rejuvenating innate immunity and overcoming treatment resistance in solid tumours" by Aoife M McGinley on November 7, 2025, during the conference's poster session.